Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gritstone bio, Inc.GRTS · Entity 80946 | See Remarks | September 27, 2018 | September 27, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gritstone bio, Inc.
Report date September 27, 2018 · Filed September 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2028-08-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-27 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The stock option vests and becomes exercisable with respect to 25% of the total number of shares on March 12, 2019. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2028-08-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-27 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable with respect to 25% of the total number of shares on March 12, 2019. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months.
F2: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on September 27, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sarepta Therapeutics, Inc.
Report date September 19, 2016 · Filed September 22, 2016
Section 16 reporting ended · disclosed 2016-09-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,490 |
Ending reported balance
After 2016-09-19 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2016-09-19 · Exercise / conversion · Acquired 10,000 · Balance 21,490 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 2 · 2016-09-19 · Sale · Disposed 10,000 · Balance 11,490 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 3 · 2016-09-19 · Exercise / conversion · Acquired 25,000 · Balance 36,490 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 4 · 2016-09-19 · Sale · Disposed 25,000 · Balance 11,490 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2021-12-22 | Direct | 3,420 |
Reported balance
After 2016-09-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-19 · Exercise / conversion · Disposed 10,000 · Balance 3,420 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2021-12-22 | Direct | 61,580 |
Reported balance
After 2016-09-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-19 · Exercise / conversion · Disposed 25,000 · Balance 61,580 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2016 Filed Sep 22, 2016 01:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Options (right to buy) · Derivative | 25,000 | $4.62 Strike: $4.62 | $115,500.00 |
DisclosureSEC source: 0001209191-16-142359 · doc4.xml · derivative · entry 6 Aphale Jayant · CIK 0001574696 · VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,580 Underlying: Common Stock · 25,000 shares Expires 2021-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 10,000 | $4.62 Strike: $4.62 | $46,200.00 |
DisclosureSEC source: 0001209191-16-142359 · doc4.xml · derivative · entry 5 Aphale Jayant · CIK 0001574696 · VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,420 Underlying: Common Stock · 10,000 shares Expires 2021-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 25,000 | $50.00 | $1,250,000.00 |
DisclosureSEC source: 0001209191-16-142359 · doc4.xml · nonDerivative · entry 4 Aphale Jayant · CIK 0001574696 · VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,490 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 25,000 | $4.62 | $115,500.00 |
DisclosureSEC source: 0001209191-16-142359 · doc4.xml · nonDerivative · entry 3 Aphale Jayant · CIK 0001574696 · VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,000 | $50.00 | $500,000.00 |
DisclosureSEC source: 0001209191-16-142359 · doc4.xml · nonDerivative · entry 2 Aphale Jayant · CIK 0001574696 · VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,490 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:31 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,000 | $4.62 | $46,200.00 |
DisclosureSEC source: 0001209191-16-142359 · doc4.xml · nonDerivative · entry 1 Aphale Jayant · CIK 0001574696 · VP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on December 11, 2015, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.